The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ABBVIE INC | Common | 00287Y109 | 721,672 | 11,656,800 | SH | DFND | 0 | 11,656,800 | 0 | ||
| ALKERMES PLC | Common | G01767105 | 325,686 | 7,535,533 | SH | DFND | 0 | 7,535,533 | 0 | ||
| NORTHWEST BIOTHERAPEUTICS INC | Common | 66737P600 | 15,065 | 25,915,937 | SH | DFND | 0 | 25,915,937 | 0 | ||
| PROTHENA CORP PLC | Common | G72800108 | 360,254 | 10,304,751 | SH | DFND | 0 | 10,304,751 | 0 | ||
| REYNOLDS AMERICAN INC | Common | 761713106 | 502,760 | 9,322,463 | SH | DFND | 0 | 9,322,463 | 0 | ||
| THERAVANCE BIOPHARMA INC | Common | G8807B106 | 198,166 | 8,733,637 | SH | DFND | 0 | 8,733,637 | 0 | ||
| BIOGEN INC | Common | 09062X103 | 4,836 | 20,000 | SH | DFND | 0 | 20,000 | 0 | ||